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Abstract
Background: Monocytes/macrophages are activated in several autoimmune diseases, including systemic sclerosis
(scleroderma; SSc), with increased expression of interferon (IFN)-regulatory genes and inflammatory cytokines,
suggesting dysregulation of the innate immune response in autoimmunity. In this study, we investigated whether
the lytic form of Epstein-Barr virus (EBV) infection (infectious EBV) is present in scleroderma monocytes and
contributes to their activation in SSc.
Methods: Monocytes were isolated from peripheral blood mononuclear cells (PBMCs) depleted of the CD19+ cell
fraction, using CD14/CD16 negative-depletion. Circulating monocytes from SSc and healthy donors (HDs) were
infected with EBV. Gene expression of innate immune mediators were evaluated in EBV-infected monocytes from
SSc and HDs. Involvement of Toll-like receptor (TLR)8 in viral-mediated TLR8 response was investigated by comparing
the TLR8 expression induced by infectious EBV to the expression stimulated by CL075/TLR8/agonist-ligand in the
presence of TLR8 inhibitor in THP-1 cells.
Results: Infectious EBV strongly induced TLR8 expression in infected SSc and HD monocytes in vitro. Markers of
activated monocytes, such as IFN-regulated genes and chemokines, were upregulated in SSc- and HD-EBV-infected
monocytes. Inhibiting TLR8 expression reduced virally induced TLR8 in THP-1 infected cells, demonstrating that innate
immune activation by infectious EBV is partially dependent on TLR8. Viral mRNA and proteins were detected in freshly
isolated SSc monocytes. Microarray analysis substantiated the evidence of an increased IFN signature and altered level
of TLR8 expression in SSc monocytes carrying infectious EBV compared to HD monocytes.
Conclusion: This study provides the first evidence of infectious EBV in monocytes from patients with SSc and links EBV
to the activation of TLR8 and IFN innate immune response in freshly isolated SSc monocytes. This study provides the
first evidence of EBV replication activating the TLR8 molecular pathway in primary monocytes. Immunogenicity of
infectious EBV suggests a novel mechanism mediating monocyte inflammation in SSc, by which EBV triggers the
innate immune response in infected cells.
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Background
Systemic sclerosis (scleroderma; SSc) is a complex auto-
immune disease characterized by immune abnormalities,
vascular damage, and fibrosis predominantly involving
the skin and lungs [1]. An aberrant innate immune response
is suspected to activate both immune and non-immune
effector cells in SSc, as evidenced by the presence of an
interferon (IFN) signature in the affected tissues and
the genetic predisposition toward genes linked to the
IFN pathways [2, 3].
Monocytes/macrophages are known to play a crucial
role in the innate immune process [4]. These cells have
been found in SSc tissues, suggesting that monocytes/
macrophages might be involved in the pathogenesis of
the disease [5, 6]. Abnormalities in monocytes have been
documented in SSc [7]. Studies have shown increased
expression of several IFN-regulatory genes, including si-
alic acid-binding Ig-like lectin 1 Siglec1/CD169 (Siglec1),
a marker of activated monocytes/macrophages, and nu-
merous monocyte inflammatory cytokines in peripheral
blood mononuclear cells (PBMCs) and sera from SSc pa-
tients, implicating dysregulation of the innate immune
response in the activation of these cells [8–11]. However,
what triggers and sustains monocyte activation in SSc
remains unclear.
Although innate immunity is classically viewed as a first
line of resistance against pathogens, little is known about
pathogens as the source of the innate immune activation
in SSc [12]. The expression of Epstein-Barr virus (EBV)
lytic mRNA and proteins in PBMCs and skin of SSc pa-
tients has been associated with aberrant antibody response
against EBV lytic antigens [13, 14], suggesting that EBV
dysregulation may be more prevalent in SSc patients. The
lytic form of EBV infection (infectious EBV) is detected by
the host innate immune system. In this regard, monocytes
have been shown to detect unmethylated viral genomes by
Toll-like receptor (TLR)9 [15], suggesting that these cells
participate in the innate immune control of EBV. Given
these observations, we sought to investigate whether EBV
infection in monocytes might contribute to their activa-
tion in SSc. Here, we demonstrate that EBV replicates in
primary human monocytes several days post-infection
(PI), and viral lytic genes strongly induce TLR8 expression
and activation of the innate immune response in healthy
donor (HD) and SSc monocytes infected with EBV. The
presence of infectious EBV in SSc is substantiated by de-
tecting the expression of EBV lytic mRNA and proteins in
freshly isolated SSc monocytes, while it is absent in mono-
cytes from HDs. Using microarray analysis, we show that
SSc monocytes carrying infectious EBV exhibit a robust
induction of the IFN signature and altered level of TLR8
expression compared to HDs. Our results suggest that
monocyte activation in SSc may be a result of aberrantly
controlled EBV infection.
Methods
Study subjects
All study subjects met the criteria for SSc as defined
previously [16]. All subjects gave written informed con-
sent. Subjects selected for this study, diffuse cutaneous
SSc (dcSSc) patients (n = 53) and normal healthy donors
(HD) (n = 34), are summarized in Table 1. All the patients
and HDs included in the study were positive for EBV ser-
ology. All dcSSc patients included in the study were naive
for immunosuppressive therapy (IT) or >6 months free of
IT. Due to the variable number of PBMCs and monocytes
obtained from the patients and controls, sets of experi-
ments performed on the same subjects are indicated in
Table 1.
PBMC and monocyte isolation
Blood was collected from EBV-seropositive HD and dcSSc
patients in CPT tubes designed for one-step cell separation
(Becton Dickinson), and PBMCs were isolated as previ-
ously described [9]. After positive selection of CD19 cells
(CD19+) using magnetic bead isolation (CD19+ selection
EasySep, StemCell), monocytes were negatively selected
using the Human Monocyte Enrichment Kit without
CD16 Depletion (EasySep, StemCell). Purity of the mono-
cyte population was determined by detection of CD163,
CD16, and CD19 mRNA expression and using flow cy-
tometry for the surface markers CD14 and CD163 (BD
Pharmingen) (Additional file 1: Figure S1A and B).
Virus preparation and EBV infection of monocytes and
THP-1 cells
Viral stocks were obtained from culture supernatants of
recombinant EBV-wt B95.8 genomes stably transfected
Table 1 Clinical and demographic characteristics of the subjects
enrolled in the study
dcSSc* HD
Number of subjects, n 53 34
Age in years, mean ± SE (range) 44 ± 1.8
(23–71)
41 ± 2.7
(23–65)
Female, % 96 94
mRSS**, mean ± SE 17 ± 0.7 –
Monocytes infected with recombinant EBV
(qPCR, Western blot and immunofluorescence
staining experiments), n
14 8
Monocytes freshly isolated (RT-PCR for DNA,
qPCR, Western blot and immunostaining
experiments), n
8 6
PBMCs (FACS analysis experiments), n 13 12
Skin biopsies (immunostaining experiments), n 18 8
*Inclusion criteria: disease duration <5 years; patients naïve for
immunosuppressive therapy (IT) or >6 months free of IT
dcSSc diffuse cutaneous systemic sclerosis, EBV Epstein-Barr virus, HD healthy
donor, mRSS modified Rodnan Skin Score, PBMC peripheral blood mononuclear
cell, qPCR quantitative polymerase chain reaction, RT-PCR real-time polymerase
chain reaction, SE standard error
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into 293 cells (293-p2089) as previously described [13].
Before infection, monocytes from SSc patients and HDs
were prepared by UV irradiation at 230 mW/cm2, using
a Stratalinker XL1500 (Stratagene, Agilent technologies,
Santa Clara, CA, USA). Given that human promyelomo-
nocytic THP-1 cells (ATCC TIB-202) are an EBV-
negative cell line, UV treatment was not performed on
the cells primed for EBV infection. Monocytes and
THP-1 cells were seeded at a density of 5 × 104 cells/well
in complete RPMI 1640 medium supplemented with
10% fetal bovine serum (FBS), and infected or mock in-
fected with p2089-wtEBV as previously described [13].
Cell treatment and reagents
Cells were seeded as indicated above; TLR-agonist stimula-
tion was performed in complete medium with the following
ligands (1 μg/ml): R837/imiquimod and CL264/9-benzyl-8-
hydroxyadenine (for TLR7), CL075-thiazoloquinoline (for
TLR8) (all from Invitrogen, Grand Island, NY, USA), IFNβ
(500 U/ml; PBLinterferone), IFNγ (500 U/ml), and tumor
necrosis factor (TNF)α (10 ng/ml) (all from R&D Systems).
After 24 h of incubation, cells were harvested and stored in
RNA lysis buffer for subsequent RNA isolation. When indi-
cated, cells were treated for 24 h with CL075 or infected
with EBV in the presence or absence of Bafilomycin-A1 (20
nM) (Sigma-Aldrich, St. Louis, MO, USA). At the indicated
times PI or after ligand stimulation, proteins were harvested
and analyzed by Western blot analysis.
Nucleic acid extraction, RNA preparation and real-time
polymerase chain reaction
DNA was extracted from monocytes using the Qiagen
Extraction Kit (Qiagen, Valencia, CA, USA) and proc-
essed as previously described [13].
Total RNA from monocytes and B lymphocytes was
extracted using an miRNAsy kit according to the manu-
facturer’s protocol (Quiagen) and processed as previously
described [13]. The synthesized cDNAs were used as tem-
plates for quantitative real-time polymerase chain reaction
(PCR) and primers used as described before [2, 13]. All
real-time PCR was carried out using StepOnePlus Se-
quence Detector (Applied Biosystems, Life Technologies,
Grand Island, NY, USA). The change in the relative ex-
pression of each gene was calculated using the ΔΔCt for-
mula choosing a healthy human subject [2]. Target and
control reactions were run on separate wells of the same
quantitative PCR plate [2].
Quantitative real-time PCR primers
Primers used to detect EBV genes and innate immune
mediator genes were designed using Primer Express soft-
ware (Applied Biosystems) and synthesized by Integrated
DNA Technologies. The primers used for quanititative
PCR, including 18S endogenous control, are summarized
in Additional file 2 (Table S1). Expression of mRNA for
the indicated genes was detected using SYBRGreen chem-
istry amplification (Applied Biosystems) as previously de-
scribed [13]. To ensure specificity of the primer set,
amplicons generated from the PCR reaction were analyzed
for specific melting temperatures by using the melting
curve software. For MCP1/CCL2, Siglec1, CXCL10, IRF5,
IRF7, OAS3, TLR2, TLR3, TLR4, TLR7, TLR9, Myd88,
IL-6, CD19, TNFα, LY6E, and 18S TaqMan primers and
probe were used (Applied Biosystems).
Microarray analysis
Microarray analysis of RNA (200 ng) was performed
using standard protocols on Affymetrix Human Gene
2.0 ST arrays at the Boston University Microarray Core.
All procedures were performed as described in the Affyme-
trix GeneChip user manual (www.affymetrix.com). CEL files
were normalized to produce gene-level expression values
using the implementation of the Robust Multiarray Average
(RMA) in the affy package (version 1.36.1). Array quality
was assessed by computing relative log expression (RLE)
and normalized unscaled standard error (NUSE) using the
affyPLM package (version 1.34.0). Differential expression
was assessed using the moderated (empirical Bayesian) t test
implemented in the limma package (version 3.14.4).
Correction for multiple hypothesis testing was accom-
plished using the Benjamini-Hochberg false discovery
rate (FDR). All microarray analyses were performed using
the R environment for statistical computing (version 2.15.1).
Western blot analysis
Monocytes were collected and washed with phosphate-
buffered saline (PBS). Cell pellets were suspended in 2×
SDS-Page buffer. Samples (30 μg) were heat denatured
with reducing agent. Cellular extracts and blotted pro-
teins were prepared and probed as previously described
[13]. Blotted proteins were probed with each primary
monoclonal antibody (mAb) respectively for BFRF1 [17, 18],
BFLF2 [19], Zta/Zebra (Argene, bioMérieux, Inc. Durham,
NC, USA), phospho-IRF7 (Cell Signaling Technology,
Danvers, MA, USA), IRF7 (Abcam, Cambridge, MA, USA),
TLR8 (Cell Signaling), and anti-β-actin-antibody (Sigma),
and then probed with secondary antibody and visualized
using a super signal chemiluminescence kit (Thermo
Scientific, Pittsburg, PA, USA).
Cytofluorimetric analysis
PBMCs were labeled with conjugated mouse mAb against
human CD14 (PE-Cy7), CD16 (APC), CD163 (PE),
CD169/siglec1 (FITC), and CD19 (APC/FITC) (BD
Pharmingen). After incubation with antibodies, the cells
were washed and then fixed with 2% formaldehyde.
Cytofluorimetric analysis was performed using a BD
FACSCanto II flow cytometer (Becton Dickinson, Mountain
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View, CA, USA). A total of 50,000 events were acquired
for each sample. Data were processed using FlowJo
software (Treestar, Inc., USA).
Immunocytochemistry/immunohistochemistry
Monocytes were stained with mouse monoclonal anti-
bodies against CD14-PE (BD Pharmingen), BFRF1 [18],
gp-350-220 [13], rabbit TLR8 (Cell Signaling), and
secondary-antibodies-Cy3-conjugated (Jackson IR, West
Grove, PA, USA), Alexafluor-350 goat-anti mouse anti-
body (Invitrogen, Grand Island, NY, USA), or 488-labeling
(Zenon kit; Invitrogen). Coverslips were mounted using
Vectashield with DAPI (Vector Laboratories, Burlingame,
CA, USA) and immunofluorescence staining was exam-
ined using a FluoView FV10i confocal microscope system
(Olympus, Center Valley, PA, USA) at 488 nm (green),
594 nm (red), and 405 nm (blue). Paraffin sections of skin
tissues were stained using mouse mAb against CD163
(AbD Serotec, Raleigh, NC, USA) and Zta/Zebra (Argene,
bioMérieux, Inc., Durham, NC, USA) as previously de-
scribed [13]. Immunohistochemical staining was examined
using the Olympus BH2 microscope.
Statistical analysis
All data are expressed as the mean ± SEM. Statistical
comparisons between groups were tested by two-tailed
t test. Significance was taken at P ≤ 0.05.
Results
De novo EBV replication occurs in primary cultured
monocytes infected with EBV-p2089
Monocytes have been identified as a potential target for
EBV infection [15]. The EBV genome has been detected
in monocyte/macrophages from patients with several
diseases, including rheumatoid arthritis and coronary
diseases, supporting the ability of EBV to infect these
cells in vivo [20–22]. Based on these observations, we
first sought to investigate whether SSc monocytes were
also capable of sustaining EBV replication.
Circulating monocytes were isolated from HDs and
SSc patients with diffuse cutaneous disease (dcSSc). UV-
treated monocytes from 14 SSc patients and 8 HDs were
infected with EBV recombinant virus (EBV-p2089). Active
EBV infection was detected in monocytes from 11 SSc pa-
tients and 5 HD, while it did not occur in 3 SSc patients
and 3 HDs 5 days PI (Fig. 1a and b). Specifically, we found
that EBV/early-lytic (BFRF1) and EBV/late-lytic (BLLF1)
genes were significantly upregulated in EBV-p2089-
infected monocytes in the majority of dcSSc (n = 11) and
HDs (n = 5), 5 days PI (Fig. 1a). Since the EBV/early-lytic
BFRF1 protein is implicated in nucleo-capsid egress and
EBV/late-lytic BLLF1/gp350-220 is expressed on the
virion envelope and on EBV producer cells, these re-
sults indicate that de novo active viral infection occurs
in monocytes, and that most dcSSc and HD monocytes
are able to sustain efficient EBV replication in vitro.
EBV replication induces TLR8 and innate immune
mediators in infected monocytes
Given that EBV replicates in primary cultured monocytes,
we next evaluated whether infectious EBV might trigger
the innate immune response in EBV-p2089-infected
monocytes that were previously UV inactivated. De novo
viral replication strongly induced expression of TLR8
mRNA in lytic-infected cells (Fig. 1c), and BFRF1/lytic
protein was associated with monocytes expressing high
levels of TLR8 (Fig. 1d), suggesting that induction of TLR8
occurs in EBV-infected monocytes. Given that TLR7 to-
gether with TLR8 represent the two nucleic acid receptors
detecting ssRNA and that TLR3 recognizes dsRNA, we
sought to evaluate whether TLR7 and/or TLR3 could also
be induced by EBV in infected monocytes. Unexpectedly,
EBV-lytic mRNAs did not increase TLR7 expression in the
infected cells (Fig. 1e), while TLR3 was only induced in
monocytes from two HDs and one dcSSc patient (Additional
file 1: Figure S2A). Moreover, we also found that EBV-p2089
induced expression of TLR9 in monocytes from a few HDs
and dcSSc patients (Additional file 1: Figure S2B), confirming
the previous observation [23]. No significant induction
of TLR2 was found in EBV-p2089-infected monocytes
(Additional file 1: Figure S2C).
EBV exploits two modes of infection: latent state and
lytic replication [24]. Further supporting the linkage be-
tween viral replication and activation of the innate immune
response, TLR8 or TLR7 expression was not induced in
monocytes latently infected by EBV, as confirmed by the
lack of infectious EBV in the cells harboring EBV-p2089
DNA (Fig. 1f and g, and h showing one representative
dcSSc patient and HD). Notably, the naive EBV genome
was expressed in the majority of dcSSc (7/8) and in some
(3/6) HD monocytes (Table 2), suggesting that the preva-
lence of EBV DNA is higher in monocytes from dcSSc pa-
tients compared to HDs. Together, these findings suggest
that newly lytic EBV mRNA is detected by TLR8 in in-
fected HD and dcSSc monocytes.
To further characterize the TLR8 innate immune re-
sponse induced by viral/lytic genes, innate immune medi-
ators were examined in EBV-p2089-infected monocytes.
MyD88 and IRF7 mRNA, as well as IRF7 protein (phos-
phorylated and total), expression was induced in the ma-
jority of infected monocytes from dcSSc patients and HDs
(Fig. 2a and b). Since IRF7 is required to induce the innate
antiviral response characterized by IFNs, IFN-regulated
genes, and inflammatory cytokines [25], we next deter-
mined whether lytic EBV might induce in EBV-p2089 in-
fected monocytes the same inflammatory genes found to
be upregulated in dcSSc monocytes. We found that ex-
pression of CXCL9, OAS3, Siglec1, and cytokines,
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including CCL2, TNFα, and interleukin (IL)-6, were ro-
bustly increased in EBV-p2089-infected monocytes
(Fig. 2a). In contrast, no upregulation of innate immune
mediators and proinflammatory cytokines was observed in
latently infected monocytes (Fig. 2c and Additional file 1:
Figure S3). To better appreciate the magnitude of innate
immune mediators induced by infectious EBV in infected
cells, in a parallel experiment, monocyte fractions not ex-
posed to the virus were stimulated with CL075, a well-
established TLR8/ligand positive control [26, 27]. We
found that TLR8 ligand stimulation significantly induced
the expression of Siglec1 and CCL2 genes in dcSSc and
HD monocytes, comparable to the induction observed by
infectious EBV in EBV-infected cells (Additional file 1:
Figure S4). Statistically, no significant differences were ob-
served in Siglec1 and CCL2 gene induction in TLR8-
stimulated and EBV-infected monocytes.
Fig. 1 EBV replication modulates TLR8 expression in monocytes in vitro. Negative selected monocytes from dcSSc patients and HDs were infected with
EBV. For total RNA and immunostaining, monocytes were harvested 5 days PI. a,b,c,e,f,g mRNA expression of EBV-lytic and TLR genes was analyzed by
quantitative PCR. Results are expressed as fold-change induction normalized by one of the mock infected healthy controls. 18S rRNA was used as internal
control. Bars represent the mean ± SEM. The two-tailed t test was used for statistical analysis. d Immunofluorescence double staining shows EBV-BFRF1-
antigen (blue) and TLR8 (red) co-expression in monocytes from one representative dcSSc and HD infected with EBV-p2089. Original magnification 60×,
scale bar = 5 μm. h PCR products of EBV DNA in monocytes from representative dcSSc and HD; DNA from Raji-EBV-positive cells and DNA from 293 were
used as positive control and negative control, respectively. GAPDH used as internal control. b, e, f and h refer to monocytes expressing EBV-p2089 latent
infection. dcSSc diffuse cutaneous systemic sclerosis, EBV Epstein-Barr virus, HD healthy donor, TLR Toll-like receptor
Table 2 EBV gene expression and DNA in circulating
monocytes and in skin macrophages of dcSSc patients
EBV protein/DNA Number of dcSSc
patients positive/tested
Number of HDs
positive/tested
BFRF1* (monocytes) 3/8 0/6
BFLF2* (monocytes) 4/8 0/6
EBER1 DNA** (monocytes) 8/8 3/6
EBER1 DNA** (B-lymphocytes) 8/8 8/8
BZLF1/Zebra monocytes
mRNA ***
4/8 0/6
CD163+/macrophages*** 6/18 0/8
*Tested by Western blot
**Tested by real-time polymerase chain reaction
***Tested by immunohistochemistry on skin sections
dcSSc diffuse cutaneous systemic sclerosis, EBV Epstein-Barr virus, HD
healthy donor
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Taken together, these results suggest that TLR8 ex-
pression and the innate immune inflammatory response
are induced by de novo infectious EBV in EBV-infected
dcSSc and control monocytes.
Infectious EBV induces TLR8 protein expression in a
TLR8-dependent and TLR8-independent manner in
infected THP-1 cells
To elucidate the role of EBV in viral-mediated TLR8 sig-
naling in monocytes, THP-1 monocytic cell line was in-
fected with EBV-p2089. UV treatment did not induce
TLR8 mRNA expression in THP-1 UV treated cells
(Additional file 1: Figure S5). Given that THP-1 cells
are negative for EBV genome expression, UV treatment
was not performed on the cells primed for EBV infec-
tion. After the exposure to recombinant EBV, 10–20%
cell/field of THP-1 cells showed cellular p2089-GFP
fluorescence at 1 h PI (Fig. 3a). EBV gp-350/late-lytic
proteins were expressed in 2–3% of the cells 1 h PI
(Fig. 3b). Kinetics of EBV infection showed a significant
increase of the BFRF1/early-lytic gene over 2–24 h,
while the LMP-1/latent gene was significantly induced
up 72 h PI (Fig. 3c). Increased expression of TLR8
mRNA was induced in EBV-infected cells by 6 h with
maximal induction at 24 h PI (Fig. 4a). In contrast, no
induction of TLR8 mRNA was observed in latently in-
fected cells at 72 h PI (Fig. 4a). TLR8 protein expression
was also induced in THP-1-EBV-infected cells (Fig. 4b). In
conjunction with TLR8, increased expression of IRF7
(phosphorylated and total) was also observed in THP-1-
infected cells (Fig. 4b). Intriguingly, we found that IRF7
expression was also induced at 2 h PI, in agreement with
the previous studies showing that EBV induces an early
innate immune response in monocytes [21, 28].
Viral ssRNA has been identified as a natural agonist of
TLR7 and TLR8 [27], and distinct RNA motifs selectively
activate TLR7- and/or TLR8-mediated innate immune re-
sponses [26]. THP-1 cells were stimulated with TLR
Fig. 2 EBV lytic genes modulate the expression of innate immune mediators, IFN-inducible genes, and proinflammatory cytokines in EBV-p2089-
infected monocytes. a,c mRNA expression of indicated innate immune mediators and cytokines was evaluated by quantitative PCR in negative
selected CD14/CD16 monocytes infected with EBV-p2089, 5 days PI. Results are expressed as the fold-change induction normalized by one of the
mock infected healthy controls. 18S ribosomal RNA levels used as internal control. Bars represent the mean ± SEM. b Western blot analysis was
performed to determine IRF7 protein (phosphorylated and total) levels in cell lysates of mock- and EBV-infected monocytes from one representative
dcSSc patient and HD, 5 days PI. β-actin was used as loading control. Fold-changes shown on the graph are normalized to mRNA expression by one
of the mock infected healthy controls. Bars represent mean ± S.E.M. The two-tailed t test was used for statistical analysis. dcSSc diffuse cutaneous
systemic sclerosis, EBV Epstein-Barr virus, HD healthy donor, IL interleukin, Siglec1 sialic acid-binding Ig-like lectin 1 Siglec1/CD169, TNF tumor necrosis factor
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ligands R837 and CL264 (for TLR7) and CL075 (for
TLR8). We found that activation of TLR8 by CL075 in-
duced expression of TLR8 and to a lesser extent IRF7 pro-
teins (Fig. 5a). In contrast, activation of TLR7/agonist
ligands failed to induce expression of TLR8 protein
(Fig. 5a). IRF7 protein was increased by stimulation of
TLR7 ligands (Fig. 5a), IFNβ, IFNγ, and TNFα, and to a
lesser extent by TLR8 ligand (Fig. 5b). Moreover, we ob-
served that IFNγ and TNFα also induced TLR8 protein
expression in THP-1 cells, although to a lesser extent than
selective TLR8 ligand stimulation (Fig. 5b). Consistent
with this finding, virally induced TLR8 stimulation was
mostly comparable to the induction observed by TLR8/
selective agonist/ligand in THP-1 cells (Fig. 6a, Additional
file 1: Figure S6A). Notably, the combination of EBV and
CL075-TLR8/ligand was more effective in inducing TLR8
(Fig. 6a).
We next investigated whether the TLR8 activation by
EBV is mediated in a TLR8-dependent manner in in-
fected THP-1 cells. We found that bafilomycin-A1, an
inhibitor of endosomal acidification and autophagy [29],
partially decreased TLR8 and IRF7 expression in THP-1
EBV-infected cells, although it strongly reduced TLR8
and IRF7 expression in CL075/TLR8 stimulated cells
Fig. 3 EBV lytic genes are expressed in THP-1 cells. THP-1 cells were infected with EBV. Total RNA and proteins were harvested at indicated time
points, processed, and analyzed by quantitative PCR and immunofluorescence. a Detection of EBV-p2089-GFP in THP-1 after 1 h PI (left: phase-contrast
light microcopy, scale bar= 0.1 mm). b Double-indirect immunofluorescence staining of THP-1 cells co-stained with anti-EBV/gp-350 antibodies.
Diaminidino-2-phenylindole (DAPI) was used as counterstaining for the nuclei. Insert: Higher magnification view for detail (arrow) Original magnification
10×; scale bar = 10 μm. c mRNA expression of indicated genes and proteins in mock-infected and EBV-infected THP-1 cells at indicated time points.
Data are expressed as the fold-change normalized to mRNA expression in a mock-infected sample for each time point. Bars represent mean ± SEM
from three separate experiments. P values calculated using two-tailed t test; *P < 0.05, **P < 0.01. EBV Epstein-Barr virus, PI post-infection
Fig. 4 TLR8 modulation during EBV infection in THP-1 cells at different time points. THP-1 cells were infected with EBV. Total RNA and proteins were
harvested at indicated time points, processed, and analyzed by quantitative PCR and Western blot. a TLR8 mRNA expression in mock-infected and
EBV-infected THP-1 cells at indicated time points. Data are expressed as the fold-change normalized to mRNA expression in a mock-infected sample
for each time point. Bars represent mean ± SEM from three separate experiments. P values calculated using two-tailed t test; *P < 0.05. b Western blot
analysis was performed to determine TLR8 and IRF7 protein (phosphorylated and total) levels in cell lysates at indicated time points post-infection (PI).
β-actin was used as loading control. EBV Epstein-Barr virus, TLR Toll-like receptor
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(Fig. 6b and c, Additional file 1: Figure S6B). Altogether,
these results suggest a role on the TLR8 response in me-
diating EBV active infection.
IFN-regulated genes and TLR8 are upregulated in freshly
purified dcSSc carrying infectious EBV
Consistent with our finding that the newly lytic EBV
mRNA possibly activates the TLR8 innate immune re-
sponse in infected monocytes, we next asked whether
viral lytic mRNA would be detected in dcSSc monocytes.
Due to the possibility of altering endogenous EBV, UV
treatment was not performed on these sets of freshly
isolated monocytes. We found expression of BZLF1/
EBV-early-lytic-transactivator mRNA in freshly isolated
monocytes from four dcSSc patients (n = 4/8) (Fig. 7a
and Table 2). cDNA sequencing confirmed BZLF1 speci-
ficity of the real-time PCR products (data not shown). In
contrast, the corresponding B-lymphocyte fraction from
dcSSc patients and the monocyte and B-lymphocyte
fractions from HDs did not express the BZLF1 gene
(Fig. 7a), although EBV DNA was detected in all B lym-
phocytes and monocytes from dcSSc patients, as well as
in B lymphocytes (n = 6/6) and in monocytes (n = 3/6)
from HDs (Additional file 1: Figure S7, and Table 2). To-
gether, these results suggest that while B lymphocytes
carry EBV latent infection, freshly isolated dcSSc mono-
cytes sustain the viral replication.
With the aim of determining whether the innate im-
mune response seen upregulated in EBV-p2089-infected
monocytes would also be increased in freshly isolated
dcSSc EBV-infected monocytes, the gene expression pro-
file was examined in dcSSc monocytes tested positive for
infectious EBV compared to HDs. Remarkably, the micro-
array analysis revealed that most of the EBV-induced
IFN-regulated genes were significantly upregulated
(FDR q < 0.25) in lytic/EBV-positive dcSSc compared to
HD monocytes (Fig. 7b, and Additional file 3: Table S2). To a
lesser extent, expression of TLR8, MyD88, IRF7, Siglec1,
CXCL10, CCL2, and TNFα was also increased in
dcSSc compared to HD monocytes (Fig. 7c). mRNA
Affymetrix data (GEO: GSE86984) are available at the
public repository Gene Expression Omnibus. Micro-
array results were confirmed by quantitative PCR in a
larger group of dcSSc patients (n = 8) and HDs (n = 6)
(Fig. 7d), further supporting that TLR8 and IFN-
regulated genes were significantly increased in dcSSc
Fig. 5 CL075/TLR8 synthetic agonist ligand, IFNγ, and TNFα induce TLR8 expression. Cellular lysates from THP-1 cells treated with TLR synthetic
ligand: a CL264 (adenine analog), R837 (Imiquimod), CL075 (3 M002), or b IFNβ, IFNγ, and TNFα or untreated were extracted after 24 h and
analyzed by Western blot. Representative immunoblots of TLR8 and IRF7 expression in whole cell lysates. β-actin was used as loading control.
IFN interferon, TNF tumor necrosis factor; TLR Toll-like receptor
Fig. 6 EBV-induced TLR8 is partially mediated by TLR8. THP-1 cells were infected with EBV in a presence/absence of CL075/TLR8 agonist ligand
and b,c with/without bafilomycin-A1 (BAF-A1). Proteins were assayed 24 h after infection and CL075/TLR8 synthetic ligand stimulation as indicated.
Representative immunoblots of TLR8 and IRF7 expression are shown. β-actin was used as loading control. EBV Epstein-Barr virus, TLR Toll-like receptor
Farina et al. Arthritis Research & Therapy  (2017) 19:39 Page 8 of 14
compared to HD monocytes. No difference in expres-
sion of TLR7, TLR3, and TLR9 was observed in dcSSc
compared to HD monocytes (Fig. 7d and data not
shown).
These results substantiate the observation that infec-
tious EBV is associated with the activation of TLR8 and
IFN proinflammatory response in dcSSc monocytes.
Segregation of Siglec1 expressing subsets on CD14/CD16
dcSSc monocytes
Circulating monocytes defined by different expression
levels of CD14 and CD16 surface markers are known to
possess distinct phenotypes and functions [30]. Moreover,
altered proportions and conversion of monocyte subsets
CD14+/CD16– into CD16+ occur in most autoimmune
diseases [31]. Given that EBV lytic infection may occur in
a distinct subset of monocytes, which could become posi-
tive for the expression of the Siglec1, we next sought to
determine whether Siglec1-positive cells might be ascribed
to a specific population of ex vivo dcSSc monocytes.
Using FACS analysis, monocytes were identified as
previously reported in three subsets: CD14+/CD16–
(classical), CD14+/CD16+ (intermediate), and CD14–/
CD16+ (non-classical) monocytes (Fig. 8a) [31, 32].
We did not find any significant difference between the
percentage of total monocytes or subsets from dcSSc
patients compared to HDs (Fig. 8b and c). Interestingly,
we found a trend towards an increased number of non-
classical monocytes expressing Siglec1 and a slight in-
crease in classical monocytes, but no difference in the
intermediate subset (Fig. 8d). These results could sug-
gest that Siglec1-activated monocytes are generally
increased in the CD14–/CD16+ non-classical subset
and to a lesser extent in the classical subset in dcSSc
patients compared to HDs.
EBV/lytic proteins are present in circulating monocytes
and in skin macrophages from patients with dcSSc
To identify whether infectious EBV might be ascribed to a
specific population of ex vivo dcSSc monocytes, CD14 and
CD16 surface markers were evaluated in freshly isolated
EBV-infected cells [30]. EBV/lytic proteins were expressed
in a subset of CD14+ and CD16+ monocytes from dcSSc
(Fig. 9a and c, arrows; Fig. 9b shows four representative
dcSSc patients) (Table 2). In contrast, we did not find any
EBV expression in circulating monocytes from six HDs
(Fig. 9b shows four representative HDs).
Fig. 7 TLR8 and IFN-inducible gene signature in freshly isolated dcSSc monocytes carrying infectious EBV. a PCR products of EBV-lytic gene in
freshly isolated monocytes (Mo) and B lymphocytes (B-ly) from two representative diffuse cutaneous systemic sclerosis (dcSSc) patients and one
healthy donor (HD); 293 and Raji cells were used as negative and positive controls, respectively. b Heatmap showing the expression of the 156
most significantly upregulated genes (moderated t test) FDR q < 0.25 in freshly isolated lytic/EBV-positive dcSSc compared to HD monocytes.
Colors are scaled within each gene so that red and blue indicate expression of values ≥2 standard deviations above and below, respectively, the
mean (white) computed across all samples. c Heatmap of the expression of select genes, with colors scaled in the same manner as in panel b.
d mRNA expression of indicated genes. Results are expressed as the fold-change normalized to mRNA expression in a single sample from HDs.
Levels of 18S ribosomal rRNA were used as an internal control. Bars represent the mean ± SEM. Values were calculated using two-tailed t test
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Given that dcSSc circulating monocytes are carrying
infectious EBV, and increased macrophages have been
shown in the perivascular areas of SSc skin [8, 33], we
next sought to determine whether skin macrophages
from dcSSc patients express EBV/lytic proteins. An esti-
mated 2–3% cell/field double positive cells for EBV/nu-
clear/immediate-early/lytic protein BZLF1/Zebra (Zebra
+) and monocyte/macrophage surface/antigen-CD163
(Zebra+/CD163+) were found in 6/18 dcSSc skin biop-
sies (Fig. 9d, Table 2). As expected, Zebra + staining was
found in the nuclei of the infected cells, while CD163
staining was spread around the cell (Fig. 9d, lower panel,
high magnification). We did not find any expression of
Zebra + or double Zebra+/CD163+ macrophages in the
skin from HDs (Fig. 9d). In general, this finding suggests
that skin macrophages represent a target of EBV infec-
tion in dcSSc patients.
Discussion
Monocyte/macrophage inflammation and TLR activa-
tion have been identified as possible contributors to the
pathogenesis of many autoimmune diseases, including
SSc. The findings presented here show that activation
of TLR8 is induced by EBV/lytic genes in HD and SSc
EBV-p2089-infected monocytes and that expression of
TLR8 and IFN innate immune mediators is significantly
increased in freshly isolated dcSSc monocytes carrying
infectious EBV compared to monocytes from HDs. This
is the first study that identifies infectious EBV in mono-
cytes from patients with SSc, and mechanistically links
EBV with activation of TLR8 and the IFN innate im-
mune response in freshly isolated dcSSc monocytes.
These data support a potential role for infectious EBV
in contributing to chronic innate immune activation in
dcSSc monocytes.
Fig. 8 Monocyte subsets and Siglec1 expression in dcSSc patients and HD. a Representative monocyte subsets from PBMCs of diffuse cutaneous systemic
sclerosis (dcSSc) patients and healthy donors (HDs) defined by the expression of CD14 and CD16 and gating by FACS analysis as CD14+/CD16– (classical,
68% HD), CD14+/CD16+ (intermediate, 2.3% HD), and CD14–/CD16+ (non-classical, 10.4 HD). b Number of monocytes (%) in HD compared to dcSSc
patients. c Frequencies of classical, intermediate, and non-classic monocyte subsets in HD and dcSSc patients. d Expression of Siglec1 in the indicated
subsets. P values calculated using two-tailed t test. Arrows and circles indicate the representative sample for each class of monocytes shown in panel a
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EBV has been reported to induce an innate immune
response characterized by strong release of IL-8 and
MCP-1 via TLR9 and TLR2 in monocytes shortly after
infection [15, 23]. Likewise, specific viral programs and
small non-coding RNA recognized by TLR7, TLR3, and
RIG-I have been reported in infected B lymphocytes and
plasmacytoid dendritic cells, suggesting that activation
of the innate immune response by EBV is dependent on
the viral programs carried in the infected cells [15, 34].
In support of these findings, we also observed that TLR9
and TLR3 were increased in a select few monocytes.
One explanation could be that viral replication may not
occur simultaneously in all EBV-infected monocytes, and
that distinct monocyte populations might also predispose
different EBV viral programs in infected cells. Consistent
with this observation, we found that monocytes from dis-
tinct SSc patients and HDs could be lytically or latently in-
fected after the same exposure time to EBV. Given that the
status of EBV infection is dependent on underlying changes
within B lymphocytes that permit the stable maintenance
of the virus genome or predispose its lytic form [35–39], it
is possible that distinct monocyte populations might also
influence the establishment of lytic or latent EBV infection.
The key observation that EBV DNA does not induce
activation of TLR8 and/or other TLR-inflammatory re-
sponses strongly indicates that viral replication might be
the prerequisite in activating the innate immune re-
sponse in the infected cells.
Although immunogenicity of infectious EBV has not
yet been taken into account, these findings now lead to
the question of which viral-gene mRNA or viral miRNA
might specifically interact with TLR8. Further investiga-
tion will be required to address this aspect.
An important aspect of this study is that almost all
dcSSc and HD monocytes were able to sustain EBV rep-
lication in vitro up to 5 days PI. Expression of BZLF1,
the EBV immediate early transactivator which promotes
the switch from latent to lytic infection, was previously re-
ported as early as 2 h PI with maximum expression at 20 h,
suggesting that the EBV replicative cycle occurs very early
in infected cells, including monocytes [21, 28, 35, 40–42].
Thus, our data extend this observation to dcSSc mono-
cytes, showing that de novo EBV replication and activation
of the IFN innate immune response could be detected up
to 5 days PI.
Activation of TLR8 by synthetic ligand mimicked the
EBV effects on TLR8, by inducing TLR8 and IRF7 mRNA
expression. Intriguingly, selective activation of TLR8 over
TLR7 has been shown to inhibit the TLR7-IFNα response,
suggesting that the interaction between these two receptors
may contribute to the regulation of the innate immune re-
sponse [43, 44]. Consistent with the observation that TLR8
upregulation inhibits the TLR7-IFNα response, we found
that expression of the BFRF1/lytic gene was associated with
a trend of TLR7 downregulation in certain infected HD and
dcSSc monocytes (Additional file 1: Figure S8), suggesting
Fig. 9 EBV-lytic proteins are expressed in dcSSc circulating monocytes and dcSSc skin macrophages. Immunofluorescence and Western blot analysis of
CD14/CD16 monocytes freshly purified from PBMCs by negative selection, and immunohistochemistry of skin sections. a, c Double immunofluorescence
shows the presence of EBV-BFRF1 antigen (green) in CD14+ (red), and EBV-gp-350-220 (red) in CD16+ (green) from two representative diffuse cutaneous
systemic sclerosis (dcSSc) patient and two healthy donors (HD). Green arrows indicate monocytes expressing EBV/lytic proteins. Original magnification 60×.
Scale bar= 10 μm. b Western blot analysis of EBV-BFRF1 and EBV-BFLF2 lytic proteins in cell lysates of dcSSc and HD monocytes; B95-8/EBV-expressing cells
and 293 were used as positive and negative control, respectively. β-actin used as loading control. d Representative immunohistologic images of CD163+
macrophages (brown) and EBV/lytic protein Zebra + (blue) cells in skin sections from dcSSc and HD. Original magnification 2× (upper panels) and 10× (inserts
and lower panels). The arrows indicate monocytes represented in the high magnification inserts. Scale bars= 5 μm
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that activation of TLR8 may be a new strategy employed by
EBV to dampen IFNα during lytic replication and control
the host innate immune system.
The mechanism for EBV-induced TLR8 expression
was in part dependent on the TLR8-activation pathway,
since infectious EBV in the presence of bafilomycin did
not completely abrogate the signaling resulting in TLR8
and IRF7 upregulation in THP-1 cells. Consistent with
our findings that infectious EBV stimulates the production
of TNFα mRNA (Fig. 2a) [45], which also upregulates
TLR8 protein in THP-1 cells (Fig. 5b), these observations
support the idea of EBV using TNFα as a mechanism to
synergize with endosomal TLR8 signaling to modulate in-
nate immune responses in infected THP-1 cells. Further
investigation will be required to address this aspect.
The relevance of the IFN innate immune response and
TLR8 in dcSSc patients has been substantiated by micro-
array analysis showing the elevated expression levels of
IFN-regulated genes, chemokines, and TLR8 mRNA in ex
vivo EBV-infected dcSSc monocytes compared to infected
HD monocytes. The possible role of TLR8 in autoimmune
diseases has been recently considered, since together with
TLR7 it is one of the two TLRs expressed on the X
chromosome [46]. Because most autoimmune diseases are
more prevalent in females, it has been postulated that ele-
vated levels of TLR8, as an X-linked gene, might play a
direct role in the pathogenesis of these diseases, including
SSc [46]. TLR8 has been implicated in the pathogenesis of
arthritis, as its overexpression causes spontaneous inflam-
matory arthritis in mice [47]. Moreover, a recent study
shows that TLR8 agonist stimulation contributes to in-
flammatory and profibrotic cytokine production in SSc
monocytes, further supporting the link between the in-
flammatory/fibrosis process and TLR8 innate immune ac-
tivation in the pathogenesis of SSc [48].
Different monocyte subsets may exert specific functions
in response to microbes. While CD14+/CD16– classical
monocytes produce more proinflammatory cytokines, in-
cluding IL-6, and production of ROS, CD14–/CD16+,
non-classical monocytes selectively produce high levels of
TNFα in response to the same trigger [30]. We found
EBV lytic proteins in ex vivo CD14+ and/or CD16+ dcSSc
monocytes suggesting that EBV might infect more than
one monocyte population in SSc. Therefore, it is conceiv-
able that induction of selective cytokines may also be
dependent on the monocyte population infected by EBV.
In this regard, although EBV-p2089 induced several
proinflammatory cytokines in HD and dcSSc monocytes
in vitro, the magnitude of the induction was dissimilar
among the primary cells (Fig. 2a), possibly reflecting the
heterogeneity in the infected monocyte populations. It is
also worth mentioning that either the innate immune re-
sponse or EBV status could be affected by the phenotype
of the infected monocytes. Thus, while specific monocyte
subsets may not permit EBV reactivation, other popula-
tions may be more permissive to EBV replication when
infected. Further studies will be needed to clarify the
functional outcomes of EBV infection among distinct
monocyte populations.
We show that expression of Siglec1 can be induced by
EBV. Previous studies reported increased level of CD169/
Sglec1 monocytes/macrophages in SSc skin, lung, and
PBMCs [8, 9, 49], suggesting that CD169+ cells might
contribute to the pathogenesis of SSc. While the func-
tional role of Siglec1 in SSc is not entirely clear, it is
generally accepted that CD169+ macrophages are in-
volved in cell-cell adhesion as well as cell-pathogen
interaction [50, 51]. Consistent with this observation,
recent studies have shown that CD169+ macrophages
were able to capture several viruses, including HIV, sug-
gesting that sialic acid on the viral envelope facilitates
HIV-I infection of macrophages through interacting with
Siglec1 [52, 53]. Although the functional role of Siglec1 in
EBV infection has not been taken into account, we specu-
late that EBV might use Siglec1 for cell-to-cell adhesion
and viral spread.
Our finding suggests that Siglec1 is inclined to be more
induced in SSc non-classical monocytes. This result is in
agreement with previous studies which reported increased
levels of CD16 and CCL2 in Siglec1-positive monocytes,
suggesting that monocytes expressing Siglec1 are more ac-
tivated to produce cytokines in SSc [8]. While the
characterization of the EBV-infected cell population re-
mains to be determined in vivo, it is possible that Siglec1-
positive CD14–/CD16+ monocytes might carry active
EBV infection. Intriguingly, non-classical monocytes have
shown the ability to adhere to the endothelium in vivo
and in vitro and to exert specific functions in the response
to viruses via TLR7/8 [30, 32]. We speculate that EBV/
Siglec1/CD14–/CD16+ monocytes might facilitate EBV
dissemination in SSc tissues by permitting the adhesion of
monocytes to the vascular endothelium in vivo.
Our data showed that skin macrophages expressed
EBV lytic protein, further suggesting that EBV-infected
monocytes might migrate into the skin and facilitate dis-
semination of EBV to endothelial cells and fibroblasts
[13]. Although this is the first report showing the pres-
ence of EBV lytic protein in dcSSc skin macrophages,
the possibility that monocytes/macrophages might serve
as reservoir and/or vehicle for EBV infection in tissue
sites is in agreement with a previous study [54].
Conclusion
This study provides the first evidence of EBV/lytic gene
mRNA activating the TLR8 innate immune pathway
and suggests a novel mechanism mediating monocyte
inflammation in SSc by which EBV triggers the innate
immune response in infected cells.
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Additional files
Additional file 1: Figure S1. Experimental setup of monocyte
purification and monocyte subsets in dcSSc patient and HD groups. (A): a
representative cytofluorimetric analysis of CD14 and CD163 expressing
monocytes pre- and post- selection from PBMCs. (B): mRNA expression of
the indicated genes evaluated in the fraction of CD19+lymphocytes and
CD14/CD16 monocytes from dcSSc patients and HDs by qPCR. Figure
S2. TLRs expression in EBV lytic infected monocytes evaluated by qPCR in
negative selected CD14/CD16 monocytes infected with EBV-p2089 5 days
post infection (PI). Figure S3. Innate immune mediators are not induced
in monocytes expressing the latent form of EBV infection in negative
selected CD14/CD16 monocytes infected with EBV-p2089, 5 days post
infection (PI). Figure S4. Increased expression of Siglec1 and CCL2 is
equally induced by EBV lytic infection and CL075/TLR8 synthetic ligand in
HD and dcSSc EBV-lytic infected monocytes. Figure S5. TLR8 mRNA
expression in UV radiated THP-1 cells. Bars represent mean ±S.E.M. from 3
separate experiments. Figure S6. (A-B) Western Blot analysis of full length
of TLR8 and IRF7 expression in EBV-infected/uninfected THP-1 cells. Figure
S7. PCR products of EBV DNA in monocytes and in B-lymphocytes from
representative dcSSc and HD; DNA from Raji-EBV-positive cells and DNA
from 293 were used as positive control and negative control, respectively.
Gapdh used as internal control. Figure S8. The role of BFRF1-lytic gene for
selective activation of TLR8 over TLR7 gene expression in EBV-p2089 in-
fected monocytes. mRNA expression of EBV lytic genes and TLR genes was
analyzed by q-PCR. Results are expressed as fold induction normalized to
each mock-infected control. 18S ribosomal RNA levels were used as internal
control. (PDF 527 kb)
Additional file 2: Table S1. Real-time PCR primers used for detection
of viral and host gene cDNAs. (DOCX 14 kb)
Additional file 3: Table S2. Gene expression profile of top induced
genes in SSc vs HD monocytes (FDR q < 0.25). (DOCX 70 kb)
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